Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1997-10-22
1999-09-28
Huff, Sheela
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
560134, 560135, 560136, 560137, 564 15, 564162, 564180, A01N 4710
Patent
active
059589710
ABSTRACT:
Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalyzed reactions.
REFERENCES:
patent: 4975278 (1990-12-01), Senter et al.
Edwards/Foster/Owen/Pringle: Cytotoxic Compounds XVII; Perkin J.C.S., 1 (1973): 2397-2402.
Benn/Creighton/Owen/White: Cytotoxic Compounds II (1961): 2365-2375.
William, D. E. V.: Prodrugs in Cancer Chemotherapy: Biochem. Soc. Trans. 14 (1986): 375-382.
Springer, C.J., J. Med. Chem., 33, (1990), 677-681.
Levy, C.C., J. Bio. Chem., 212, (1967), 2933-2938.
Pratt, A. G., J. Med. Chem., 243, (1968), 6367-6372.
Levy, C.C., J. Bio. Chem., 242, (1967), 2933-2938.
McCullough, J.L., J. Bio. Chem., (1971), 7207-7213.
Goldman, P., Proc. N.A.S., 58, (1967), 1299-1306.
Rosowsky, A., Progress in Medicinal Chemistry, 26, (1990, 145-159.
Adamson, P.C., J. Clinical Oncology, 10, (1992), 1359-1364.
Bisset, G.M.F., J. Med. Chem., 35, (1992), 859-866.
Sherwood, R.F., Eur. J. Biochem., 148 (1985), 447-453.
Bagshawe K.D., Br. J. Cancer, 58, (1988) 700-703.
Springer C.J., J. Med. Chem., 33 (1990), 677-681.
Antoniw C.J., Br. J. Cancer, 62, (1990), 909-914.
Mann, J., Tetrahedron, 46, (1990), 5377-5382.
Springer, C.J. Eur. J. Cancer, 27, (1991), 1361-1366.
Bagshawe, K.D., Disease Markers, 9, (1991), 233-238.
Springer, C.J., Anti-Cancer Drug Design, 6, (1991), 467-479.
Springer, C. J., Drugs of the Future, 18(3), (1993), 212-215.
Bagshawe, K.D., Monoclonal Antibodies and Immunoconjugates, (1990), 95-102.
Springer, C. J., Monoclonal Antibodies -Antibodies in Clinical Oncology, (1991), 185-191.
Bagshawe, K.D. Proc. 4th Intern. Conf. on Monoclonal Antibody Immunoconjugates for Cancer, (1989), 178.
Sharma, S. K., Disease Markers, 9 (1991), 225-231.
Springer, C. J. Proc. Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, RPMS, UK 34, (1989).
Bagshawe, K.D., Biol. Proc. 17th Intern. Soc. Oncodevelopmental Biology & Medicine, Germany (1989).
Melton, R. G., Proc. NATO Adv. Studies Inst., Greece (1994).
Antoniw, P., Proc., 18th Intern. Soc. Oncodevelopment Biology & Medicine, Russia (1990).
Sharma, S. K. Proc. 18th Intern. Soc. Oncodevelopment Biology & Medicine, Russia (1990).
Springer, C. J., Proc. Adv. in Applications of Monoclonal Antibodies in Clinical Oncology RPMS, UK 23 (1990).
Sunters, C. J. Biochem. Pharmacology, 44(1), (1992), 59-64.
Blakey, D. C., Proc. 9th Intern. Hammersmith Meeting, Porto Carras, Greece 33, (1992).
Springer, C. J., Proc. 9th Intern. Hammersmith Meeting, Advances in Applications of Monoclonal Antibodies in Clinical Oncology, Porto Carras, Greece 35 (1992).
Sunters, A., Br. J. Cancer, 60 (1992).
Blakey, D. C., Br. J. Cancer, 67 (1992).
Sharma, S. K., Proc. Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, London, UK 53 (1989).
Sharma, S. K. Antib. Immunoconj. & Radiopharm. 6 (1993), 74.
Sharma, S. K., Proc. 10th Intern. Hammersmith Meeting -Advances in Applications of Monoclonal Antibodies in Clinical Oncology, Paphos, Cyprus, (1993), 24-25.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm, (1992), 133.
Springer, C J., Antib. Immunoconj. & Radiopharm., (1991), 226.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm, (1991), 204.
Springer, C. J., Antib. Immunoconj. & Radiopharm., (1992), 127.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm., 4 (1991), 915-922.
Springer, C. J., Proc. 3rd Intern. Conf. on Monoclonal Antibody Immunoconjugates for Cancer, UCSD, USA (1988),43.
Springer, C. J., Antib. Immunoconj. & Radiopharm. 3 (1990), 61.
Bagshawe, K. D., Proc. 4th Int. Conf. on Monoclonal Antibody Immunoconjugates for Cancer, USCD, USA (1989) 178.
Sharma, S K., Antib. Immunoconj. & Radiopharm., 5, (1992) 348.
Springer, C. J., Antib. Immunoconj. & Radiopharm., 6 (1993), 74.
Springer, C. J., Comparasion of Half Lives and Cytotoxicity of Prodrugs & their Activated Drugs in Antibody Directed Enzyme Prodrug Therapy (Adept); Proc. Targeted Cancer Therapy, London, 1991.
Springer, C. J., Proc 10th Int. Hammersmith Meeting -Advances in Applications of Monoclonal Antibodies in Clinical Oncology, Cyprus (1993).
Bagshawe, K.D., (1990) Proc. Advances in Applications of Monoclonal Antibodies in clerical Oncology, London, U.K.
Sharma et al., (1990) Antibody directed enzyme prodrug therapy (ADEPT) in human tumor xenograft models Br. J. Cancer, 62; 487.
Parasmickiene, Izv. Akad. Nasuk. SSSR Ser. Khim (3) 649-51 (1971).
G. Parasmickiene et al., `Synthesis of amino acid derivatives acylated by vol. 75, No. 5; Aug. 2, 1971, p. 564, Abstract No. 36603m. dicarboxylic amino acids and their derivatives` Chemical Abstracts, vol. 75, No. 1; Jul. 5, 1971, p. 526, Abstract No. 6299z.
M. H. Benn et al., `Cytotoxic Compounds. Part II. Some Amides of the "Nitrogen Mustard" Type.` Journal of the Chemical Society 1961; pp. 2365-2375.
P.D. Edwards et al., `Cytotoxic compounds Part XVII. o-,m-, and N,N-bis(2-chloroethyl)-N'-methyl-p-phe nylenediamine as sources of biologically active carbamates`; Journal of the Chemical Society, Perkin Transactions a, No. 20, 1973 pp. 2397-2402.
Karpavicius. Izv. Akad. Nauk. SSR Ser. Khim (3) 2150-3 (1970).
Bagshawe, K.D., Tumour Site Activation of Cytotoxic Agent; Advances in Applications of Monoclonal Antibodies in Clinical Oncology; Hammersmith Hosptial Meeting; 1988.
Bagshawe, K.D., Antibody Directed Enzymes Activate Anti-Cancer Prodrugs Biochem Soc Trans; 1990.
Canevari et al., Annals of Oncology, vol. 5, pp. 698-701 (1994).
Hermenlin et al., Behring Inst. Mitt., No. 82, pp. 197-215 (1988).
Burke Philip John
Dowell Robert Ian
Mauger Anthony Brian
Springer Caroline Joy
Cancer Research Campaign - Technology Limited
Huff Sheela
Zeneca Limited
LandOfFree
Chemical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703916